Future Medicinal Chemistry, a journal published by Future Science Ltd., UK, has published a mini focus dedicated to developments in the area of rheumatology, with contributions from academic experts based in Europe, North America and Asia.
Rheumatology is a topic at the forefront of medicinal chemistry research with increasingly strong interest being invested into exploring novel compounds that modulate pathways and molecular targets in rheumatic diseases. Traditional small-molecule therapies, such as gold salts, have been superseded by biologics including the TNF inhibitor etanercept; however, medicinal chemistry has progressed and an increasing number of new small- and large-molecules are being developed as therapeutic candidates.
The mini focus provides a snapshot of the current state of this active field. The issue comprises comprehensive reviews and topical opinion pieces by leading experts in the field. Topics include the implications of targeting visfatin and sphingosine kinases in rheumatoid arthritis, the potential use of cannabinoids, and the risks of targeting proteins and pathways that are involved in both rheumatic disease progression and resolution.
Future Medicinal Chemistry provides a monthly platform (18 issues annually) for reviews and original research for the ever-expanding and diversifying pharmaceutical chemistry community, by showcasing milestones in R&D and featuring expert analysis of emerging developments. The journal is supported by an international Editorial Board headed by Professor Iwao Ojima (State University of New York at Stony Brook, USA) and Professor David Thurston (King's College London, UK). The journal is indexed by Medline/Pubmed, ISI and other major services.
The special focus issue can be accessed from the Future Medicinal Chemistry website http://www.future-science.com/toc/fmc/4/6.
